Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03926013 · ClinicalTrials.gov registry record · Phase 1
A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors
A Phase 1 study of Neoplasms, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 7
- Study locations
NCT03926013: Completed Phase 1 study of Neoplasms, sponsored by Janssen Research & Development.
NCT03926013 is a Phase 1 study of Neoplasms that has completed, run by Janssen Research & Development. The registered enrollment target is 40 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03926013, a Phase 1 study of Neoplasms, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
Primary Outcome
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Conditions Studied
Interventions
- DRUG JNJ-63898081
Study Locations (7)
California
- University of California, San Francisco - San Francisco
Maryland
- NIH Clinical Center - Bethesda
New York
- Columbia University Medical Center - New York
Utah
- University of Utah - Salt Lake City
Washington
- University of Washington - Seattle
British Columbia
- British Columbia Cancer Agency - Vancouver
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 1 |
What the finished NCT03926013 record still lists
NCT03926013 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which JNJ-63898081 is the first listed.
NCT03926013 lists 7 locations in 7 states (California, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT03926013 about?
NCT03926013 is a clinical study titled "A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors". The main purpose of this study are to determine the recommended Phase 2 dose (RP2D) regimen and the maximum tolerated dose, and to determine the safety of JNJ-63898081.
What is the current status of trial NCT03926013?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-05-01. Estimated completion is 2021-09-02.
What conditions does trial NCT03926013 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03926013?
The interventions under investigation include: JNJ-63898081 (DRUG).
Who is sponsoring clinical trial NCT03926013?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03926013 being conducted?
This trial has 7 study locations across California, Maryland, New York, Utah, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03926013's enrollment target sits among peer trials
40 120th of 158 higher than 37 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI